Iqirvo (Elafibranor)

Elafibranor, the active ingredient in Iqirvo, is a PPAR α/δ agonist presented as an oral formulation for oral use. It is indicated for the treatment of primary biliary cholangitis in adults, targeting metabolic and inflammatory pathways to help manage liver disease progression. GNH USA supplies Iqirvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iqirvo (elafibranor) is indicated for the treatment of primary biliary cholangitis, a chronic autoimmune liver disease characterized by progressive destruction of intra‑hepatic bile ducts and associated inflammation and fibrosis. The drug targets metabolic and inflammatory pathways to modify disease progression. Primary biliary cholangitis: helps reduce liver inflammation and fibrosis, aiming to improve biochemical markers of disease activity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements. - Abdominal pain: discomfort in the upper abdomen. - Headache: transient head pain. - Pruritus: itching sensation. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Elevated liver enzymes: may indicate hepatic injury. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: inflammation of the pancreas. - Hepatic decompensation: worsening liver function. - Acute renal failure: sudden loss of kidney function. - Thromboembolic events: blood clot formation.

Before initiating therapy, clinicians should consider several safety measures. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess cardiovascular risk: evaluate for existing heart disease. - Evaluate renal function: adjust use in patients with severe impairment. - Review concomitant medications: check for potential interactions. - Avoid in patients with known hypersensitivity to elafibranor. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Elafibranor may interact with other medicines, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase elafibranor exposure. - Strong CYP3A4 inducers: may reduce therapeutic effect. - Bile acid sequestrants: can lower absorption of the drug. Moderate Interactions (Monitor Closely): - Statins: monitor for increased muscle toxicity. - Anticoagulants: watch for altered clotting parameters. - Oral contraceptives: may affect hormonal efficacy. - Antidiabetic agents: monitor blood glucose levels. - NSAIDs: assess for additive gastrointestinal risk.